Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-25T12:04:22.760Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacogenetic markers to predict safety of antipsychotics in adolescents experiencing acute psychotic episodes

Published online by Cambridge University Press:  01 September 2022

D. Ivashchenko ,
K. Akmalova ,
E. Grishina ,
Y. Shevchenko  and
D. Sychev
D. Ivashchenko*
Affiliation:
Russian Medical Academy of Continuous Professional Education, Child Psychiatry And Psychotherapy, Moscow, Russian Federation
K. Akmalova
Affiliation:
Russian Medical Academy of Continuous Professional Education, Molecular Medicine, Moscow, Russian Federation
E. Grishina
Affiliation:
Russian Medical Academy of Continuous Professional Education, Molecular Medicine, Moscow, Russian Federation
Y. Shevchenko
Affiliation:
Russian Medical Academy of Continuous Professional Education, Child Psychiatry And Psychotherapy, Moscow, Russian Federation
D. Sychev
Affiliation:
Russian Medical Academy of Continuous Professional Education, Clinical Pharmacology And Therapeutics, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There are relatively fewer pharmacogenetic studies of antipsychotics in adolescents than in adult patients. The development of personalized pharmacotherapy is promising.

Objectives

Identify the most significant pharmacogenetic predictors of antipsychotic safety in adolescents experiencing acute psychotic episodes

Methods

The study included 101 adolescents diagnosed with acute polymorphic psychotic disorder at the time of admission (F23.0-9 according to ICD-10). All patients were taking an antipsychotic as their main treatment for 14 days. Children’s Global Assessment Scale (CGAS), Positive and Negative Symptoms Scale (PANSS), Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I), UKU Side Effects Rating Scale (UKU SERS), Sympson-Angus Scale (SAS), Barnes Akathisia rating scale (BARS) were used. All study participants underwent pharmacogenetic testing of pharmacokinetic and pharmacodynamic factors.

Results

CYP2D6 “intermediate” metabolism increased the risk of developing an adverse reaction by a trend of significance (OR=2.616 (95% CI 0.950-7.203); p=0.063). Carriage of HTR2A rs6313 was associated with a lower score on the UKU SERS “Other Symptoms” subscale (Beta=(-0.289); p=0.003) and an objective score on the BARS akathisia severity scale (Beta=(-0.217); p=0.029). DRD3 rs324026 carriers had a lower BARS akathisia scale score (Beta=(-0.349); p=0.004); DRD3 rs6280 carriers had a lower SAS extrapyramidal symptom severity scale score (Beta=(-0.351); p=0.003). Carriers of ANKS1B rs7968606 were associated with a higher SAS scale score (Beta=0.237; p=0.017).

Conclusions

We proposed that genotyping of CYP2D6*4, *10, DRD3 rs324026 (C allele), DRD3 rs6280 (C allele), HTR2A rs6313 (TT genotype) and ANKS1B rs7968606 (T allele) will predict the high risk of intolerance to antipsychotics in adolescents with acute psychotic episodes.

Disclosure

No significant relationships.

Keywords

AdolescentsSafetyAntipsychoticspharmacogenetics
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S69
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.